These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37381590)

  • 21. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis.
    Xiong L; Cai Y; Zhou X; Dai P; Wei Y; Zhao J; Tang H
    Future Oncol; 2022 Mar; 18(7):883-896. PubMed ID: 34825576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
    Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
    Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience.
    Salati M; Ghidini M; Paccagnella M; Reggiani Bonetti L; Bocconi A; Spallanzani A; Gelsomino F; Barbin F; Garrone O; Daniele B; Dominici M; Facciorusso A; Petrillo A
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Management of Gastric Cancer Treatment Regimens.
    Boilève J; Touchefeu Y; Matysiak-Budnik T
    Curr Top Microbiol Immunol; 2023; 444():279-304. PubMed ID: 38231223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
    Lu Z; Yang S; Luo X; Shi Y; Lee JS; Deva S; Liu T; Chao Y; Zhang Y; Huang R; Xu Y; Shen Z; Shen L
    Gastric Cancer; 2022 Sep; 25(5):943-955. PubMed ID: 35778636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.
    Wang J; He Y; Zhang B; Lv H; Nie C; Chen B; Xu W; Zhao J; Cheng X; Li Q; Tu S; Chen X
    Front Oncol; 2022; 12():924149. PubMed ID: 35719979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of PD-L1-negative and driver-gene-negative advanced nonsquamous non-small-cell lung cancer: An updated systematic review and meta-analysis.
    Chai Y; Wu X; Zou Y; Zhang X; Bai H; Dong M; Duan J
    Thorac Cancer; 2022 Nov; 13(22):3124-3132. PubMed ID: 36168110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
    Xiang J; Gong W; Sun P; Wang X; Liu A
    J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
    Zheng Z; Guo Y; Zou CP
    Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
    Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
    Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer.
    Cen S; Xu H; Liu Z; Zhao R; Pan H; Han W
    Clin Exp Immunol; 2022 May; 207(3):318-328. PubMed ID: 35553632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy.
    Chong X; Li Y; Lu J; Feng X; Li Y; Zhang X
    Hum Cell; 2024 Jan; 37(1):258-270. PubMed ID: 37889437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
    J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
    Evrard C; Louvet C; Hajbi FE; Fiore FD; Malicot KL; Aparicio T; Bouché O; Laurent-Puig P; Bibeau F; Lecomte T; Lièvre A; Guimbaud R; Kim S; Zaanan A; Sokol H; Chibaudel B; Desrame J; Pierre S; Gonzalez D; Lepage C; Tougeron D
    Dig Liver Dis; 2021 Apr; 53(4):420-426. PubMed ID: 33358124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.
    Xu T; Wang W; Bao R; Xia X; Zhang J; Huang M; Chen X; Wang R; Zhang H; Liu X; Li Q; Shu Y
    J Gastrointest Oncol; 2023 Feb; 14(1):175-186. PubMed ID: 36915465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy in advanced gastric cancer, is it the future?
    Coutzac C; Pernot S; Chaput N; Zaanan A
    Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab for the treatment of gastric cancer.
    Kamath SD; Kalyan A; Benson AB
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.